Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial
Authors: Van Rie A, Conceição E, Ndebele F, Wells F, Paulse A, Mekonnen E, Ngarega M, Trang T, Bohlela S, Sibeko Z, Segwaba P, Verboven L, Heupink T, Fuertes M, Rennie V, Dippenaar A, Rigouts L, Setlhare L, Ogunbayo A, VanderSpoel Van Dyk A, Conradie F, Maartens G, Potgieter S, Black J, Fanampe B, Abrams S, Churchyard G, Warren R, Charalambous S.
Journal: The Lancet Respiratory Medicine, 14:521-532 (2026)
DOI: 10.1016/S2213-2600(26)00095-0
Abstract
This file is not available for download.
Citation: Van Rie A, Conceição E, Ndebele F, Wells F, Paulse A, Mekonnen E, Ngarega M, Trang T, Bohlela S, Sibeko Z, Segwaba P, Verboven L, Heupink T, Fuertes M, Rennie V, Dippenaar A, Rigouts L, Setlhare L, Ogunbayo A, VanderSpoel Van Dyk A, Conradie F, Maartens G, Potgieter S, Black J, Fanampe B, Abrams S, Churchyard G, Warren R, Charalambous S. Whole genome sequencing precision medicine strategy to shorten treatment for rifampicin-resistant tuberculosis (SMARTT): a pragmatic, randomised, single-blind phase 4 trial The Lancet Respiratory Medicine, 14:521-532 (2026).